NEW ARTICLE: MEBENDAZOLE kills Ovarian Cancer Cells that are resistant to Chemotherapy - once again, a cheap anti-parasitic outperforms a $500 million key chemotherapy agent
2021 paper by Huang - Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways
Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women.
Due to the lack of effective early detection strategies, over 80% of ovarian cancers are usually diagnosed with metastatic lesions
While the first-line systemic therapy requires the combined use of platinum-based agents and paclitaxel, many ovarian cancer patients have recurrence and eventually succumb to chemoresistance.
The antiparasitic drug mebendazole (MBZ) is one of the most promising drugs with repurposing potential
Almost identical to Fenbendazole, a drug being repurposed to treat Turbo Cancers caused by Pfizer and Moderna COVID-19 mRNA Vaccines, Mebendazole is also being repurposed for CANCER.
Mebendazole was able to inhibit and kill Ovarian cancer cells that were resistant to cisplatin chemotherapy.
By the way, Cisplatin is a $500 million chemotherapy drug.
Mebendazole costs $2 a pill, and you can find it in many online pharmacies based in India
Article Link in photo to avoid shadowban, just re-type the URL in the 1st photo at the top, into your browser to access
@TuckerCarlson@JoeRogan
#TurboCancer